Bococizumab
Lua error in package.lua at line 80: module 'strict' not found.
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | Proprotein convertase subtilisin/kexin type 9 (PCSK9) |
Clinical data | |
Legal status |
|
Routes of administration |
Subcutaneous injection |
Identifiers | |
CAS Number | 1407495-02-6 |
ATC code | none |
PubChem | SID: 194168554 |
IUPHAR/BPS | 7730 |
ChEMBL | CHEMBL3137349 |
Chemical data | |
Formula | C6414H9918N1722O2012S54 |
Molecular mass | 145.1 kg/mol |
Bococizumab[1] (RN316)[2] is a drug in development by Pfizer targeting PCSK9 to reduce LDL cholesterol.[3]
Description
Bococizumab is a monoclonal antibody that inhibits PCSK9, a protein that interferes with the removal of LDL. LDL levels are a major risk factor for cardiovascular disease.[4]
Clinical trials
A phase 2b study of statin patients was presented at the 2014 American College of Cardiology. Monthly or bimonthly injections resulted in significantly reduced LDL-C at week 12.
The Phase 3 SPIRE trials plan to enroll 17,000 patients to measure cardiovascular risk. High risk and statin intolerant subjects will be included.
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
<templatestyles src="Asbox/styles.css"></templatestyles>
<templatestyles src="Asbox/styles.css"></templatestyles>
- Pages with reference errors
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Hypolipidemic agents
- PCSK9 inhibitor
- Monoclonal antibody stubs
- Cardiovascular system drug stubs